Company intelligence / Profile preview

VISUfarma

Ownership: Private
Employees: ~175
Development stage: Commercial

Overview

VISUfarma has a broad commercial portfolio of ophthalmic products and devices for conditions such as dry eye, glaucoma, eyelid hygiene disorders, and more. The company operates across Europe with a direct sales force in major markets and distributes to over twenty countries through exclusive partners. No specific clinical trial results are highlighted; the focus is on commercialization of approved products.

Therapeutic areas: Ophthalmology
Modalities: Small moleculesMedical devicesFood supplements
Industry: Biotech

Drug pipeline

4 assets

VisuXL

3 more assets in the full pipeline.

Request access →

Partnerships

Partners with US licensing companies for European distribution; specifics not named.

Beyond the preview

Go deeper on VISUfarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VISUfarma.

Explore the full profile